LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
在接受醋酸阿比特龙联合泼尼松治疗的初治转移性去势抵抗性前列腺癌(mCRPC)患者中,保留促性腺激素释放激素(LHRH)的治疗:随机II期SPARE试验的结果
期刊:Prostate Cancer and Prostatic Diseases
影响因子:5.8
doi:10.1038/s41391-022-00533-6
Ohlmann, Carsten-Henning; Jäschke, Michelle; Jaehnig, Peter; Krege, Susanne; Gschwend, Jürgen; Rexer, Heidrun; Junker, Kerstin; Zillmann, Roger; Rüssel, Christoph; Hellmis, Eva; Suttmann, Henrik; Janssen, Martin; Marin, Jan; Hübner, Andreas; Mathers, Michael; Gleißner, Jochen; Scheffler, Michael; Feyerabend, Susan; Telle, Jens; Klier, Jörg; Stöckle, Michael